CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70173 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Rubin Lubomirov und 5 weiteren Autor:innen. Beteiligte Einrichtung: PharmaMar S.A., Clinical Pharmacology Department, Clinical Development, Colmenar Viejo, Madrid, Spain. Hauptthemen laut MEDLINE: Carbolines, Heterocyclic Compounds, 4 or More Rings, Cytochrome P-450 CYP3A, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Lurbinectedin is an oncogenic transcription inhibitor indicated for the treatment of small cell lung cancer (SCLC), which has also shown activity against other malignancies. In this work, two independent cohorts of 180 (discovery cohort) and 719 (validation cohort) cancer patients receiving lurbinectedin in Phases I, II, or III clinical trials were enrolled. Using a population pharmacokinetic (popPK) model of the discovery cohort, patients with extremely high ( n = 10, cohort 1) and low ( n = 10, cohort 2) etaCL values (i.e., a variable used as a surrogate of unexplained CL interindividual variability) were identified. They were sequenced for 42 candidate genes involved in lurbinectedin pharmacokinetics. A total of 34 variants located in 20 genes were significantly associated with lurbinectedin etaCL; the best nine hits (located in CYP3A5, CYP3A4, ABCB1, ARNT, NR5A2, NR1H4 , and FOXA3 ) were subsequently genotyped in the validation cohort. A strong additive association between CYP3A4 and CYP3A5 genotypes (informed as a CYP3A activity score [AS] variable) and lurbinectedin clearance (CL) and exposure was confirmed, for example, patients with an AS of 3, 2, or 1 showed a 2.3‐, 1.6‐, and 1.5‐fold higher total lurbinectedin CL compared to those with an AS of 0 and 2.3‐, 1.8‐, and 1.6‐fold higher unbound lurbinectedin CL. In conclusion, preemptive CYP3A genotyping may offer a valuable approach for personalizing treatment with lurbinectedin in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PharmaMar S.A., Clinical Pharmacology Department, Clinical Development, Colmenar Viejo, Madrid, Spain.
ORCID-Profile: Rubin Lubomirov, Salvador Fudio, Eduardo Asín-Prieto, Pablo Zubiaur
Zitieren
APA
Lubomirov, R., Pérez-Ramos, L., Fudio, S., Asín-Prieto, E., Ibarra-Gómez, L., & Zubiaur, P. (2025). CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin. Clinical and Translational Science. https://doi.org/10.1111/cts.70173
Vancouver
Lubomirov R, Pérez-Ramos L, Fudio S, Asín-Prieto E, Ibarra-Gómez L, Zubiaur P. CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin. Clinical and Translational Science. 2025. doi:10.1111/cts.70173
BibTeX
@article{Lubomirov2025,
author = {Lubomirov, Rubin and Pérez-Ramos, Laura and Fudio, Salvador and Asín-Prieto, Eduardo and Ibarra-Gómez, Laura and Zubiaur, Pablo},
title = {CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70173}
}
EUVIMED